The Ziltivekimab Cardiovascular Outcomes Study (ZEUS) tested whether ziltivekimab, an interleukin-6 inhibitor, could reduce major cardiovascular events in adults with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation. Although the drug markedly lowered C-reactive protein and interleukin-6, the trial found no significant reduction in the combined risk of heart attack, stroke, or cardiovascular death compared with placebo. The results were presented at the American Heart Association’s Scientific Sessions 2026 and simultaneously published in The New England Journal of Medicine.
The trial enrolled more than 6,300 participants across 38 countries, all with confirmed atherosclerotic cardiovascular disease, clinically significant chronic kidney disease, and high-sensitivity C-reactive protein levels of at least 2 mg/L. Most also had hypertension, type 2 diabetes, or heart failure, reflecting a population with substantial unmet clinical needs. Despite a 64% reduction in hs-CRP and a 76% reduction in interleukin-6, the primary endpoint occurred in 561 participants on ziltivekimab and 565 on placebo. Overall deaths were similar between groups (538 vs. 542). Serious infections were slightly more common with ziltivekimab (20% vs. 18%).
Lead author Paul M. Ridker, M.D., M.P.H., FAHA, of Harvard Medical School and Mass General Brigham, emphasized that the findings should not diminish the broader evidence linking inflammation to cardiovascular risk. “While the lack of clinical benefit in ZEUS is disappointing, we already know from prior research that targeting inflammation can significantly reduce cardiovascular risk, so it’s important not to overinterpret these findings,” Ridker said. He noted that previous trials with interleukin-1 inhibition and low-dose colchicine demonstrated benefit, and that the ZEUS population may have had disease too advanced for anti-inflammatory therapy to alter outcomes.
The researchers observed that participants with higher baseline hs-CRP or interleukin-6 levels remained at greater risk throughout the trial, reinforcing inflammation’s role in this population. Ridker suggested that future efforts should explore downstream interleukin-6 inhibition in earlier-stage disease and upstream targeting of the NLRP3 inflammasome. “This trial demonstrates in real time just how research progress is made and how to move forward for better patient care,” he said.
The findings also highlight the importance of managing interconnected conditions. The American Heart Association’s 2026 guideline for cardiovascular-kidney-metabolic (CKM) syndrome stresses the links between heart disease, kidney disease, diabetes and obesity. Practical steps such as those in Life’s Essential 8—including healthy eating, physical activity, and controlling blood pressure, cholesterol, and blood sugar—remain foundational. Ridker stressed that measuring inflammation is critical: “We can’t treat what we don’t know about.” The trial was funded by Novo Nordisk.


